Search
The Research Process
Science and Innovation - Animal Health Innovation - Parasiticides
COVID-19
COVID-19
First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development
First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development
What we do
Boehringer Ingelheim is a multinational corporation with divisions dedicated to Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.
Even nature isn’t perfect
Even nature isn’t perfect
The wise choice in mastitis prevention
The wise choice in mastitis prevention
Boehringer Ingelheim increases commitments to sustainable development
Boehringer Ingelheim increases commitments to sustainable development
Global Careers Page
Join a global team of more than 52,000 passionate and talented individuals dedicated to improving the health of humans and animals worldwide.
Who are we?
Started in 1885 by Albert Boehringer, this independent family-owned company has grown into a top contributor in Human Pharma and Animal Health.
Accessibility Plan
Accessibility Plan
Partnering
Partnering
Andreas Lenk
Andreas Lenk, Head of Legal and Compliance Germany, discusses his role supporting human pharma and animal health business in legal and compliance matters.
Partnering at Boehringer Ingelheim Canada
Partnering at Boehringer Ingelheim Canada
Partnering at Boehringer Ingelheim Canada
Partnering at Boehringer Ingelheim Canada
Partnering at Boehringer Ingelheim Canada
Partnering at Boehringer Ingelheim Canada
Partnering at Boehringer Ingelheim Canada
Partnering at Boehringer Ingelheim Canada
Livestock
Livestock
Meet our Team
Find all our contact information here as well as information on where you can meet us virtually or in person. You can also find out how to submit your opportunity to our BD&L team
Mental Disorders
Mental Disorders
Retinal Diseases
Retinal Diseases
Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER-IPF study
Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER-IPF™ study
Working at Boehringer Ingelheim
Working at Boehringer Ingelheim
Equine
Equine
Sustainable Development
Sustainable Development